Docetaxel and S-1 treatment for patients with metastatic breast cancer

Docetaxel and S-1 treatment for patients with metastatic breast cancer - KBCOG 07

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1091220030

Enrollment

Registered

2009-08-13

Start date

2009-08-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anthracycline resistant metastatic breast cancer

Interventions

Intervention type:DRUG Name of intervention:Docetaxel Dose form / Japanese Medical Device Nomenclature:INJECTION,CAPSULE Route of administration / Site of application:INTRAVENOUS DRIP,ORAL Dose per ad

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Histologically or cytologically proven as breast cancer 2.Metastatic or recurrent breast cancer 3.Four weeks after the last administration of endcrine therapy 4.One year after the last administration of Docetaxel 5.Two weeks after the radiation therapy 6.Performance Status:0?2 7.Age 20 to 74 year old

Exclusion criteria

Exclusion criteria: 1.Suspected infection 2.Abundant of pleural effusion and ascites 3.Simultaneous or metachronous (within 5 years) double cancers , with the exception of intramucosal tumor curable with local therapy 4.Decetaxel resistant 5.Grade 2 edema 6.Interstitial pneumonia 7.Brain metastasis with clinical manifestation 8.HB antigen positive 9.HER 2 positive 10.Pregnant or lactating women or women of childbearing potential

Design outcomes

Primary

Measure	Time frame
Response rate	—

Secondary

Measure	Time frame
Overall survival, Progression - free survival, Rate of adverse event, Tumor control rate	—

Countries

Japan

Contacts

Public ContactToshitaka Okuno

Nishi-kobe Medical Center

okuno-surg@nmc-kobe.org+81-78-997-2200

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026